NCT00810758

Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691

A Phase 1, Randomized, Placebo Controlled, Blinded (3rd Party Open), Sequential, Multiple-Dose Escalation Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691 In Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of PF-04878691.

Conditions

• Hepatitis C Virus

Interventions

Type	Name	Description
DRUG	PF-04878691 3mg	Oral solution, 3mg, twice weekly, 2 weeks
DRUG	PF-04878691 6mg	Oral solution, 6mg, twice weekly, 2 weeks
DRUG	PF-04878691 9mg	Oral solution, 9mg, twice weekly, 2 weeks

Timeline

• Start date: 2009-01-01
• Primary completion: 2009-11-01
• Completion: 2009-11-01
• First posted: 2008-12-18
• Last updated: 2009-12-01

Locations

1 site across 1 country: United States